Ann: Lumos Appoints Henry Schein as US Distributor for FebriDx, page-75

Just saying also, the CLIA waiver opens up a dramatic and "transformational" amount of opportunities for product purchase however its easy to estimate and track potential as mentioned via pascal sales to LDX via AT1 quarterlies.

If we know that AT1 for "x" period sold "x" number of cassettes to NG and LDX, we can assume a minimum to maximum number of potential sales. Currently appears that NG average around 100,000 units a quarter of the cassette from AT1. The difference to LDX.

https://hotcopper.com.au/threads/ldx-chart.7496921/page-1070?post_id=72111546 Here is my original post.

The way I read it, 100K units to NG on average and 50K to LDX per quarter.

(50,000 units / 25 per box) = 2000 boxes

2000 x $450 per box = $900,000 per quarter in product?

If US takes off and all product sold in the quarter ongoing, there could be potential for $900k+ in sales globally.

Add in for this year $10M in Hologic TLIIQ product and the ongoing average services revenue of $6.8M USD per FY (rolling 3 year average)

Potential for $18.8Million FY revenue if all receipted and all sold? in this quarter and next?

Just my ball park numbers.